论文部分内容阅读
Background Cardiovascular disease is one of the leading causes of death worldwide.Clopidogrel,as a cornerstone of oral antiplatelet treatment,is widely used along with aspirin in the secondary prevention of ischemic heart disease.However,about 4% to 30% of patients do not display adequate antiplatelet response due to the wide inter-individual variability in the inhibitory effect of clopidogrel on platelet aggregation.